Clinical Trial Update: ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

View source ↗

Summary

Clinical trial update notes expanded-access use of a recombinant Bacillus Calmette-Guérin (ResQ132EX) for Non-muscle invasive bladder cancer under ImmunityBio's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ResQ132EX (Recombinant Bacillus Calmette-Guérin)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NMIBC | Status: AVAILABLE